Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.
Adoptive transfer of in vivo generated antigen-specific donor-derived T-cells is increasingly recognized as an effective approach for the treatment or prevention of EBV lymphomas and cytomegalovirus infections complicating allogeneic hematopoietic cell transplants. This review examines evidence from preclinical experiments and initial clinical trials to critically assess both the potential and current limitations of adoptive transfer of donor T-cells sensitized to selected minor alloantigens of the host or to peptide epitopes of proteins, differentially expressed by clonogenic leukemia cells, such as the Wilms tumor protein, WT-1, as a strategy to treat or prevent recurrence of leukemia in the post-transplant period.
The Transplantation and Leukemia Service of the Department of Medicine and the Immunology and Molecular Pharmacology Programs at Memorial Sloan Kettering Cancer Center, United States. oreillyr@mskcc.org
Richard J
RJ
O'Reilly
Tao
T
Dao
Guenther
G
Koehne
David
D
Scheinberg
Ekaterina
E
Doubrovina
D019264:Adoptive Transfer; D000595:Amino Acid Sequence; D000818:Animals; D002986:Clinical Trials as Topic; D018984:Epitopes, T-Lymphocyte / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007938:Leukemia / Q000276:immunology / Q000517:prevention & control / Q000628:therapy; D051379:Mice; D008969:Molecular Sequence Data; D055502:Secondary Prevention; D013601:T-Lymphocytes / Q000637:transplantation*; D014184:Transplantation, Homologous / Q000009:adverse effects*; D025721:WT1 Proteins / Q000235:genetics / Q000276:immunology
D018984:Epitopes, T-Lymphocyte; D025721:WT1 Proteins